Neurogene (NGNE)
28.99
+0.98 (3.50%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
June 9, 2026 6:47 AM - StreetInsider
Form 8-K Neurogene Inc. For: Jun 08
June 8, 2026 7:33 AM - SEC Filing
Neurogene completes dosing in gene therapy trial for Rett syndrome
June 8, 2026 7:31 AM - StreetInsider
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
June 8, 2026 7:30 AM - BizWire
Form 8-K Neurogene Inc. For: Jun 03
June 4, 2026 4:41 PM - SEC Filing
Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70
June 3, 2026 6:42 AM - StreetInsider
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026 4:01 PM - BizWire
Neurogene (NGNE) PT Raised to $65 at Craig-Hallum
May 15, 2026 9:42 AM - StreetInsider
Neurogene (NGNE) Misses Q1 EPS by 139c
May 12, 2026 5:28 PM - StreetInsider
Form 8-K Neurogene Inc. For: May 12
May 12, 2026 4:07 PM - SEC Filing
Form 10-Q Neurogene Inc. For: Mar 31
May 12, 2026 4:05 PM - SEC Filing
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
May 12, 2026 4:05 PM - BizWire
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
May 12, 2026 6:00 AM - BizWire
Form 4 Neurogene Inc. For: May 06 Filed by: Cvijic Christine Mikail
May 8, 2026 11:51 AM - SEC Filing
Form 4 Neurogene Inc. For: May 05 Filed by: Shafer Christina
May 7, 2026 12:36 PM - SEC Filing
Form 144 Neurogene Inc. Filed by: Cvijic Christine Mikail
May 6, 2026 4:14 PM - SEC Filing
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026 4:01 PM - BizWire
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 28, 2026 7:30 AM - BizWire
Guggenheim Reiterates Buy Rating on Neurogene (NGNE)
April 28, 2026 6:10 AM - StreetInsider
Form 3 Neurogene Inc. For: Apr 20 Filed by: Shafer Christina
April 20, 2026 6:27 PM - SEC Filing
Form 8-K Neurogene Inc. For: Apr 20
April 20, 2026 7:33 AM - SEC Filing
Neurogene names Christy Shafer as chief commercial officer
April 20, 2026 7:30 AM - StreetInsider
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 20, 2026 7:30 AM - BizWire
Form ARS Neurogene Inc. For: Dec 31
April 16, 2026 4:23 PM - SEC Filing
Form DEFA14A Neurogene Inc.
April 16, 2026 4:16 PM - SEC Filing
Form DEF 14A Neurogene Inc. For: Jun 03
April 16, 2026 4:16 PM - SEC Filing
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 8, 2026 4:01 PM - BizWire
Neurogene (NGNE) PT Lowered to $180 at Canaccord
April 6, 2026 6:35 AM - StreetInsider
Form 4 Neurogene Inc. For: Mar 26 Filed by: Cvijic Christine Mikail
March 30, 2026 5:49 PM - SEC Filing
Form 4 Neurogene Inc. For: Mar 26 Filed by: McMinn Rachel
March 30, 2026 5:48 PM - SEC Filing
Form 4 Neurogene Inc. For: Mar 26 Filed by: Jordan Julie
March 30, 2026 5:48 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
March 26, 2026 6:48 AM - StreetInsider
Form S-8 Neurogene Inc.
March 24, 2026 4:18 PM - SEC Filing
Form 10-K Neurogene Inc. For: Dec 31
March 24, 2026 4:05 PM - SEC Filing
William Blair on Neurogene (NGNE): dosing update further de-risks NGN-401 profile
March 24, 2026 10:50 AM - StreetInsider
Leerink Partners stays Outperform on Neurogene (NGNE) following Q4 results; cites de-risked path
March 24, 2026 10:28 AM - StreetInsider
Form 8-K Neurogene Inc. For: Mar 24
March 24, 2026 7:32 AM - SEC Filing
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
March 24, 2026 7:30 AM - BizWire
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cobb Stuart
March 17, 2026 6:02 PM - SEC Filing
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cvijic Christine Mikail
March 17, 2026 6:01 PM - SEC Filing
Form 144 Neurogene Inc. Filed by: Cobb Stuart
March 13, 2026 4:20 PM - SEC Filing
Full Article List
